KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Accumulated Expenses: 2020-2022

Historic Accumulated Expenses for AbCellera Biologics (ABCL) over the last 3 years, with Dec 2022 value amounting to $19.3 million.

  • AbCellera Biologics' Accumulated Expenses fell 82.64% to $3.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was $3.1 million, marking a year-over-year decrease of 82.64%. This contributed to the annual value of $19.3 million for FY2022, which is 14.04% down from last year.
  • AbCellera Biologics' Accumulated Expenses amounted to $19.3 million in FY2022, which was down 14.04% from $22.5 million recorded in FY2021.
  • AbCellera Biologics' 5-year Accumulated Expenses high stood at $27.1 million for FY2020, and its period low was $19.3 million during FY2022.
  • For the 3-year period, AbCellera Biologics' Accumulated Expenses averaged around $23.0 million, with its median value being $22.5 million (2021).
  • Data for AbCellera Biologics' Accumulated Expenses shows a maximum YoY declined of 17.08% (in 2021) over the last 5 years.
  • Yearly analysis of 3 years shows AbCellera Biologics' Accumulated Expenses stood at $27.1 million in 2020, then declined by 17.08% to $22.5 million in 2021, then fell by 14.04% to $19.3 million in 2022.